亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台，协助业界发掘知识产权贸易商机，并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权，或是制造商需要购买技术以提高操作效能，又或是知识产权配套服务供应商，你将会从本网站发掘到有用的知识产权贸易资讯。

返回搜索结果

Chromeno[4,3,2-de]isoquinolines as Potent Dopamine Receptor Ligands

总结: A compound developed by Purdue University researchers, dinoxyline(8,9-dihydroxy-1,2,3,11b-tetragydrichromeno[4,3,2-de]isoquinoline), provides a novel class of therapeutic agents for any disorder that can be treated by drugs affecting dopamine receptors. Where dihydrexidine is ten-fold D1:D2 selective and dinapsoline is five-fold D1:D2 selective, dinoxyline has an equally high affinity for both D1 and D2 receptors. This is surprising considering the structure of this new compound in comparison to related work with other dopamine agonists. The unexpected result suggests that dinoxyline may bind to the D2 receptor in another way, which could translate into unanticipated therapeutic benefits.

技术优势: Useful in treating certain cognitive disorders and dementiaPotent anti-hypertensive effects Provides novel strategies to treat schizophrenia and drug addiction

*Background: Reduced dopamine transmission is known to be a cause of Parkinson's disease. In the United States alone, 500,000 people suffer from this disease, with approximately 50,000 cases diagnosed each year. While a dopamine precursor, levodopa, can be used to alleviate dopamine depletion, it has a very short pharmacokinetic life and increased doses are required over time to achieve desired therapeutic results. Dopamine agonist drugs have been used to activate post synaptic dopamine receptors and allow the available dopamine in the brain to bind efficiently to these receptors. These agonists can be used in monotherapy applications or in conjunction with the standard levodopa therapy.

*Web Links: Purdue Office of Technology CommercializationPurdueInnovation and EntrepreneurshipDavid NicholsPurdue Medicinal Chemistry and Molecular Pharmacology

欲了解更多信息，请点击这里